The UK Court of Appeal has completely overturned a lower tribunal’s intervention, clearing the path for the Competition and Markets Authority (CMA) to potentially reinstate a £70 million fine against pharmaceutical companies Pfizer and Flynn. The highly anticipated ruling marks a resounding victory for the antitrust regulator in its decade-long crusade against drug price-gouging.
The legal battle stems from a 2022 decision by the CMA, which found that Pfizer and Flynn had exploited their dominant market positions to radically inflate the price of phenytoin sodium capsules, a critical anti-epilepsy medication relied upon by thousands of patients. Between 2012 and 2016, Pfizer escalated its supply prices by 780% to 1,600%. Flynn then distributed the capsules to UK wholesalers and pharmacies at prices that dwarfed its own overhead costs. This compounding pricing model ultimately drove retail costs up by 2,300% to 2,600% compared to historical baselines, causing the annual expenditure of the National Health Service (NHS) on the drug to spike overnight from £2 million to roughly £50 million.
While the specialist Competition Appeal Tribunal (CAT) agreed in November 2024 that the firms had indeed violated competition laws, the tribunal chose to throw out the CMA’s specific legal and economic reasoning. In an unusual maneuver, the CAT used its own analytical framework to remake the decision and issue its own modified £69 million penalty, accusing the antitrust regulator of employing a biased and flawed methodology. Both the drug companies and the CMA subsequently filed cross-appeals with the higher Court of Appeal.
The Court of Appeal has now rejected the tribunal’s overreach in its entirety. The high court explicitly ruled that the CAT was wrong to set aside the regulator’s findings, concluding that the tribunal had fundamentally misread and mischaracterized the CMA’s heavily documented economic data. Furthermore, the appeal judges soundly dismissed the tribunal’s allegations of regulatory bias, clarifying that the length and thoroughness of the CMA’s pricing analysis over time showed zero evidence of predetermination or unobjective behavior.
Because the tribunal erred in striking down the CMA’s case in the first place, the Court of Appeal ruled that the CAT lacked any legal basis to remake the decision. The court also noted that the tribunal’s rewritten decision was itself crippled by procedural unfairness. Moving forward, the appellate court will review final legal submissions from all involved parties before formally determining whether to fully reinstate the CMA’s original 2022 infringement ruling and the complete £70 million enforcement fines.
